Cambrex and Eli Lilly: A pioneer for biotech development!

Cambrex and Eli Lilly: A pioneer for biotech development!

In a groundbreaking step, Cambrex, a leading company for order development and production, announced a strategic partnership with Eli Lilly and Company on December 5, 2024. This agreement enables the Biotech cooperation partners from Lilly Catalyze360 to accelerate access to expanded clinical development capacities. Through this cooperation, Cambrex will provide its extensive service in research and development, especially for new test medication, which should significantly accelerate the development of drugs, such as Oots.at

The Cambrex team will work with Lilly Catalyze360-Explor & D, the Department of Early External Innovation of Lilly, to provide significant resources such as active ingredients, medicines, analytical services and F & e-expertise. This innovative partnership is implemented in particular in the Cambrex facility in Longmont, Colorado, which specializes in the early development of new medicines. "We are pleased to support Lilly's mission to promote external biotech partners in product development," said Brandon Fincher, President of Early Palphase Development at Cambrex, and emphasized the flexibility and scientific excellence of the services offered, as well as in the reporting of MarketScreener.com was emphasized.

The agreements include support in all phases of medication development, process optimization to the production of active ingredients to the wording and production, including compliance with legal standards for quality assurance. Through these comprehensive services, the partnership aims to accelerate the innovation process in the biopharmaceutical area and to significantly shorten the time until new medication is launched.